Effect of different adjuvants on PCV2-associated lesions
Iowa State University Animal Industry Report 2005. Ninety, 12-14 day old pigs were randomly assigned to five groups. Group 1 (n=19) pigs were vaccinated with a Mycoplasma hyopneumoniae (M. hyopneumoniae) vaccine with an oil-in-water adjuvant (RespiSure; Pfizer Animal Health, Inc.). Group 2 (n=17) pigs were vaccinated with a commercial M. hyopneumoniae vaccine with an aqueous adjuvant (Carbopol) (Suvaxyn Respifend MH; Fort Dodge Animal Health, Inc.). Group 3 (n=18) pigs were vaccinated using an oil-in-water adjuvanted vaccine containing the same amount and type of M. hyopneumoniae antigen as in group 2. Group 4 (n=18) pigs were vaccinated using an aluminum hydroxide adjuvanted vaccine containing the same amount and type of M. hyopneumoniae antigen as in group 2. Group 5 (n=18) pigs served as the controls and were sham-vaccinated with saline. Pigs were injected with 2 mL of one of the four M. hyopneumoniae vaccines at four and again at six weeks of age. PCV2 was inoculated intranasally on the day of the second vaccination at 6 weeks of age. Half of the pigs were necropsied at 21 days post inoculation (DPI). The remaining pigs were necropsied at 35 DPI. There were no differences among groups in clinical disease scores. At 21 DPI all vaccinated groups had significantly (p<0.05) more severe lymphoid depletion than the saline injected group. At 35 DPI group 1 pigs had significantly (p<0.05) higher amounts of PCV2 DNA in serum than pigs in groups 2, 4, and 5 as determined by quantitative real-time PCR. There was a significant (p<0.05) increase in the severity of lymphoid depletion in the lymph nodes, tonsil, and spleen in groups 1 and 3 compared to groups 2, 4, and 5. Group 3 had significantly (p<0.05) higher amounts of PCV2 antigen within lymph nodes, tonsil, and spleen compared to groups 2, 4 and 5. The results confirm that all adjuvants tested enhanced PCV2-induced lesions and oil-in-water products used in this study had a more severe effect.